Safety of and antibody response to the BNT162b2 COVID-19 vaccine in adolescents and young adults with underlying disease-Reference-Cited by-同舟云学术

Safety of and antibody response to the BNT162b2 COVID-19 vaccine in adolescents and young adults with underlying disease

Published:2023-01 Issue:1 Volume:29 Page:61-66
ISSN:1341-321X
Container-title:Journal of Infection and Chemotherapy
language:en
Short-container-title:Journal of Infection and Chemotherapy

Author:

Shoji Kensuke^ORCID,Funaki Takanori^ORCID,Yamada Masaki^ORCID,Mikami Masashi,Miyake Kozue,Ueno Saki,Tao Chiaki,Myojin Shota,Aiba Hiroyuki^ORCID,Matsui Toshihiro,Ogimi Chikara^ORCID,Kato Hitoshi^ORCID,Miyairi Isao^ORCID

Funder

National Center for Child Health and Development

Publisher

Elsevier BV

Subject

Infectious Diseases,Pharmacology (medical),Microbiology (medical)

Reference17 articles.

1. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting;Dagan;N Engl J Med,2021

2. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine;Polack;N Engl J Med,2020

3. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents;Frenck;N Engl J Med,2021

4. Serology characteristics of SARS-CoV-2 infection after exposure and post-symptom onset;Lou;Eur Respir J,2020

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Improvement of Adaptive Immune Responses towards COVID-19 Following Diphtheria–Tetanus–Pertussis and SARS-CoV-2 Vaccinations in Indonesian Children: Exploring the Roles of Heterologous Immunity;Vaccines;2024-09-09

2. Safety and antibody response of the BNT162b2 SARS-CoV-2 vaccine in children aged 5–11 years with underlying diseases: A prospective observational study;Journal of Infection and Chemotherapy;2024-08

3. Association between use of antipyretics and antibody titers after two doses of the BNT162b2 SARS-CoV-2 vaccine in adolescents and young adults with underlying diseases;Journal of Infection and Chemotherapy;2023-09

4. COVID-19 in immunocompromised children and adolescents;Clinical and Experimental Pediatrics;2023-05-15

5. Tozinameran;Reactions Weekly;2023-01-07